Two recent studies have identified genetic and cellular markers that may allow clinicians to predict severe inflammatory bowel disease (IBD) earlier and understand why inflammation persists even after visible healing. The findings, drawn from data covering more than 43,000 patients and detailed cellular mapping of gut tissue, suggest that personalised treatment strategies could soon move from concept to clinical reality in gastroenterology.
Background Context
IBD encompasses Crohn’s disease and ulcerative colitis, conditions characterised by chronic inflammation of the gastrointestinal tract. Disease severity and progression vary widely between individuals, making it difficult for clinicians to predict which patients will require advanced therapies or surgery and which will remain stable on conventional treatment. Recent advances in genetic sequencing and single-cell analysis have opened new avenues for understanding the biological drivers behind these differences, offering hope that treatment can be tailored to individual risk profiles rather than applied uniformly.
Key Findings
Researchers from the Wellcome Sanger Institute and collaborators analysed genetic data from over 43,000 IBD patients and identified a specific variant within the HLA-DRB1 gene, designated HLA-DRB1*01:03. This marker is present in approximately one in 20 patients with IBD and is associated with more severe disease outcomes, including a higher likelihood of requiring colectomy and an increased need for advanced therapies. The identification of this variant suggests that genetic testing could be used to stratify patients by risk at diagnosis, enabling closer monitoring and earlier escalation of treatment for those most vulnerable to disease progression.
In parallel, a separate study mapped gene activity across more than 50 cell types in the gut, analysing over one million cells from patients with Crohn’s disease and healthy volunteers. The research revealed that even after visible inflammation has resolved, stem cells in the gut lining retain a molecular signature of previous inflammation. Genes responsible for immune signalling remain active, creating what the authors describe as a molecular scar. This persistent cellular change may explain why some patients experience recurrent flares and do not respond as expected to standard therapies. The study also identified a subset of macrophages expressing the ITGA4 gene that drive inflammation via the JAK/STAT pathway, a mechanism already targeted by JAK inhibitors in clinical use.
Clinical Relevance
These findings have practical implications for IBD care. The identification of HLA-DRB1*01:03 as a marker of severe disease offers a potential pathway toward risk stratification at diagnosis, allowing clinicians to identify patients who may benefit from early intensive therapy. Understanding the molecular scarring that persists in gut stem cells provides insight into why some patients remain prone to relapse and may guide the development of therapies that address these long-term cellular changes. The detailed cellular atlas generated by the second study, available as the online resource IBDverse, equips researchers with a tool to explore where inflammation originates and persists, potentially informing more precise therapeutic targets.
References
- Wellcome Sanger Institute. Press release: IBD patients with severe disease could be identified and treated earlier due to new genetic marker. [Accessed 2025].
- News-Medical.Net. Gut cell study discovers lasting molecular scars of Crohn’s disease. [Accessed 2025].
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.